Fig. 1: Characterisation of adult skin fibroblast-derived hiPSC lines. | Cell Death & Disease

Fig. 1: Characterisation of adult skin fibroblast-derived hiPSC lines.

From: Establishment of stable iPS-derived human neural stem cell lines suitable for cell therapies

Fig. 1

a Phase contrast of hiPSC#1, hiPSC#2 and hiPSC#3. b Immunofluorescence images showing expression of OCT4 (green) and TRA-1-60 (red) in hiPSCs lines. Nuclei are counterstained with DAPI (blue). c Histograms showing mRNA expression of OCT4, LIN28, L-MYC and SOX2 in hiPSCs with respect to non-nucleofected, wild-type fibroblasts (Fibrowt). Data are normalised on actin expression, are shown as log10 fold changes (f.c.) and represent the mean ± SEM of three experiments in duplicate. d Histograms showing the absence of exogenous genes expression after five–six passages of hiPSC amplification. Nucleofected fibroblasts (Fibronf) are used as positive control. Data are normalised on actin expression, are shown as log10 fold changes (f.c.) and represent the mean ± SEM of three experiments in duplicate. e Growth curves of hiPSC-derived teratomas. f Histological analysis of teratomas generated by hiPSCs after subcutaneous injection in immunodeficient mice. Representative hematoxylin-eosin images showing the presence of ectodermal derivatives (sebaceous gland for hiPSC#1 and hiPSC#2, neuroepithelial rosette with evident melanin deposits for hiPSC#3), mesodermal derivatives (cartilage for hiPSC#1 and hiPSC#3, adipose tissue for hiPSC#2) and endodermal derivatives (intestinal epithelium for hiPSC#1 and non-keratinised epithelial lining for hiPSC#2 and hiPSC#3). Scale bars: in a and b = 50 μm, in f = 20 μm for hiPSC#1 and 10 μm for hiPSC#2 and hiPSC#3